Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de investigación para ver cuánto CagriSema reduce el azúcar en sangre y el peso corporal en comparación con el placebo en personas con diabetes tipo 2 tratadas con dieta y ejercicio (REIMAGINE 1)

28 de septiembre de 2026 actualizado por: Novo Nordisk A/S

Eficacia y seguridad de cagrilintida y semaglutida (CagriSema) coadministradas s.c. en dosis de 2,4 mg/2,4 mg y 1,0 mg/1,0 mg una vez a la semana versus placebo en participantes con diabetes tipo 2 no controlada adecuadamente con dieta y ejercicio

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

189

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Al Ahsa, Arabia Saudita, 36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah, Arabia Saudita, 21423
        • National Guard Hospital - Jeddah
      • Riyadh, Arabia Saudita, 11525
        • King Fahad Medical City
      • Riyadh, Arabia Saudita, 12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh, Arabia Saudita, 12769
        • King Salman Bin Abdulaziz Hospital
    • California
      • Huntington Park, California, Estados Unidos, 90255
        • Nat Res Inst Huntington Park
      • Northridge, California, Estados Unidos, 91325
        • Valley Clinical Trials, Inc.
      • Santa Ana, California, Estados Unidos, 92701
        • Southern California Dermatology
    • Florida
      • Hollywood, Florida, Estados Unidos, 33024
        • Encore Medical Research LLC
      • Orlando, Florida, Estados Unidos, 32819
        • Headlands Research Orlando
      • Weston, Florida, Estados Unidos, 33331
        • Encore Medical Research of Weston
    • Kansas
      • Newton, Kansas, Estados Unidos, 67114
        • Alliance for Multispec Res
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Troy, Michigan, Estados Unidos, 48098
        • Arcturus HC PLC Troy Med Res
    • New York
      • West Seneca, New York, Estados Unidos, 14224
        • Southgate Medical Group, LLP
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Summit Research Network Oregon Inc.
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Holston Medical Group
    • Texas
      • Amarillo, Texas, Estados Unidos, 79124
        • Amarillo Medical Specialists
      • Austin, Texas, Estados Unidos, 78704
        • Elligo Clin Res Centre
      • Brownsville, Texas, Estados Unidos, 78526
        • Headlands Research Brownsville
      • Dallas, Texas, Estados Unidos, 75230
        • Velocity Clinical Res-Dallas
      • San Antonio, Texas, Estados Unidos, 78233
        • Northeast Clinical Research of San Antonio
      • Shavano Park, Texas, Estados Unidos, 78231
        • Consano Clinical Research, LLC
      • Sugar Land, Texas, Estados Unidos, 77479
        • Sugar Lakes Family Practice PA
      • Weslaco, Texas, Estados Unidos, 78596
        • Valley Diab. & Endo Comp Ctr
    • Virginia
      • Newport News, Virginia, Estados Unidos, 23606
        • TPMG Clinical Research
      • Budapest, Hungría, 1032
        • Szent Margit Rendelőintézet Nonprofit Kft.
      • Budapest, Hungría, 1102
        • PVN Kutató Kft.
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Hungría, 4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungría, 4405
        • Borbánya Praxis E.Ü. Kft.
      • Bergamo, Italia, 24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Catanzaro, Italia, 88100
        • Policlinico Mater Domini Università di Catanzaro
      • Milan, Italia, 20132
        • IRCCS Ospedale San Raffaele Milano
      • Roma, Italia, 00161
        • Azienda Ospealiero Universitaria Policlinico Umberto I
      • Bialystok, Polonia, 15-351
        • Osteo-Medic s.c. A. Racewicz, J. Supronik
      • Bialystok, Polonia, 15-797
        • Renew Clinic Sp. z o.o.
      • Lodz, Polonia, 90-338
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
      • Warsaw, Polonia, 02-507
        • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
      • Warsaw, Polonia, 00-710
        • NBR Polska Tomasz Klodawski
      • Zamość, Polonia, 22-400
        • Velocity Nova Sp. z o.o.
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, Polonia, 35-055
        • Centrum Medyczne Medyk Sp. z o.o.
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100853
        • Chinese People's Liberation Army General Hospital-Endocrinology
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang, Jiangsu, Porcelana, 212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Ji'Nan, Shandong, Porcelana, 250000
        • Jinan Central Hospital
      • Jinan, Shandong, Porcelana, 250000
        • Jinan Central Hospital
      • Belgrade, Serbia, 11080
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Serbia, 11080
        • Clinical Hospital Centre Zemun
      • Belgrade, Serbia, 11000
        • CHC Zvezdara, Clinical department for endocrinology
      • Zaječar, Serbia, 19000
        • Policlinic for diabetes

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes >=30 days before screening
  • HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
  • Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: CagriSema Dose 2

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Comparador de placebos: Placebo Dose 2

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Comparador activo: Cagrisema Dose 1

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Comparador de placebos: Placebo Dose 1

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in glycated haemoglobin (HbA1c)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as percentage (%)-points.

From baseline (week 0) to end of treatment (week 40)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Relative change in body weight
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in %.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=15% body weight reduction
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Periodo de tiempo: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Periodo de tiempo: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Change in Fasting Plasma Glucose (FPG)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in millimoles per liter (mmol/L).

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=5% body weight reduction
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=20% body weight reduction
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Change in waist circumference
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in centimeters (cm).

From baseline (week 0) to end of treatment (week 40)
Change in systolic blood pressure (SBP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in millimeters of mercury (mmHg).

From baseline (week 0) to end of treatment (week 40)
Change in diastolic blood pressure (DBP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in mmHg.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Total cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Triglycerides
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Free fatty acids
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Non-HDL cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Periodo de tiempo: At end of study (week 52)

Measured as count of participants.

At end of study (week 52)
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.

Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Physical Component Summary score
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Mental Component Summary score
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

From baseline (week 0) to end of treatment (week 40)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

From baseline (week 0) to end of treatment (week 40)
Change in leptin
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in nanograms per milliliter (ng/mL).

From baseline (week 0) to end of treatment (week 40)
Change in soluble leptin receptor
Periodo de tiempo: From baseline (week 0) to end of treatment (week 40)

Measured in ng/mL.

From baseline (week 0) to end of treatment (week 40)
Number of Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of events.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Periodo de tiempo: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Periodo de tiempo: From baseline (week 0) to end of treatment + 7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment + 7 weeks (week 47)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de marzo de 2024

Finalización primaria (Actual)

1 de octubre de 2025

Finalización del estudio (Actual)

22 de diciembre de 2025

Fechas de registro del estudio

Enviado por primera vez

15 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

15 de marzo de 2024

Publicado por primera vez (Actual)

21 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NN9388-4895
  • 2022-502677-42 (Otro identificador: European Medical Agency (EMA))
  • U1111-1283-0404 (Otro identificador: World Health Organization (WHO))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .